Overview of Dr. Donovan
Dr. Laura Donovan is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and James J. Peters Veterans Affairs Medical Center. She received her medical degree from Emory University School of Medicine and has been in practice 5 years. She is one of 485 doctors at New York-Presbyterian Hospital and one of 210 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Neurology. She has more than 10 publications and over 200 citings.
Office
710 West 168th Street
New York, NY 10032
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2013 - 2016
Brown UniversityResidency, Internal Medicine, 2012 - 2013
Emory University School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2021 - 2025
NJ State Medical License 2022 - 2025
NY State Medical License 2016 - 2025
RI State Medical License 2012 - 2013- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 34 citationsExploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's diseaseLaura E. Donovan, Eric B. Dammer, Duc M. Duong, John Hanfelt, Allan I. Levey
Alzheimer's Research & Therapy. 2013-06-13 - 55 citationsQuantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standardsNicholas T. Seyfried, Yair M. Gozal, Laura E. Donovan, Jeremy H. Herskowitz, Eric B. Dammer
Journal of Proteome Research. 2012-05-04 - 43 citationsWidely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.Laura Donovan, Ashley V Arnal, Shih-Hsiu Wang, Yazmin Odia
CNS Oncology. 2016-09-12
Lectures
- Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies.2019 ASCO Annual Meeting - 6/1/2019
- A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Karen Killilea, 80, Dies; Turned Disability into TriumphDecember 18th, 2020- Researchers Report Promising New Therapy for Recurrent Pediatric Brain CancersMay 1st, 2020
CAR T Therapy Helps Treat Pediatric Brain TumorsApril 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
